Most Read This Week
- Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
- Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer
- Adjuvant Atezolizumab vs Observation in Muscle-Invasive Urothelial Carcinoma
- Alpelisib Plus Fulvestrant in PIK3CA-Mutated, HR+ Advanced Breast Cancer After a CDK4/6 Inhibitor
- Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Studies
Recently Updated
- Smoking, Radiation Therapy, and Contralateral Breast Cancer Risk in Young Women
- Avelumab Plus Standard-of-Care Chemoradiotherapy vs Chemoradiotherapy Alone in Locally Advanced HNSCC
- Delayed Immune-Related Adverse Events With Anti–PD-1–Based Immunotherapy in Melanoma
- Interval Cancers Down With Digital Breast Tomosynthesis
- Health-Related Quality of Life in Patients With Microsatellite Instability–High or Mismatch Repair–Deficient Metastatic Colorectal Cancer Treated With First-Line Pembrolizumab vs Chemotherapy